Clinical Trial

Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-10-08; most recent amendment 2025-11-06.
Status change: Not Yet Recruiting → Recruiting 2025-01-10
Trial Details
NCT Number NCT06635889
Lead Sponsor University of Chicago
Conditions Nephrolithiasis
Enrollment 116 participants
Start Date 2025-03-26
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-10